S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
NASDAQ:IMMX

Immix Biopharma Stock Forecast, Price & News

$5.84
+0.01 (+0.17%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.46
$6.08
50-Day Range
N/A
52-Week Range
$2.85
$8.68
Volume
806,296 shs
Average Volume
31.14 million shs
Market Capitalization
$44.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.


Immix Biopharma logo

About Immix Biopharma

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMMX
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$44.24 million
Optionable
Not Optionable

Company Calendar

Today
1/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1399th out of 1,417 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Immix Biopharma (NASDAQ:IMMX) Frequently Asked Questions

When did Immix Biopharma IPO?

(IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at $5.00-$6.00 per share.

What is Immix Biopharma's stock symbol?

Immix Biopharma trades on the NASDAQ under the ticker symbol "IMMX."

When does the company's quiet period expire?

Immix Biopharma's quiet period expires on Tuesday, January 25th. Immix Biopharma had issued 4,200,000 shares in its IPO on December 16th. The total size of the offering was $21,000,000 based on an initial share price of $5.00. During the company's quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Immix Biopharma?

Shares of IMMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immix Biopharma's stock price today?

One share of IMMX stock can currently be purchased for approximately $5.84.

How much money does Immix Biopharma make?

Immix Biopharma has a market capitalization of $44.24 million.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.